It is the first-and-only approved FcRn blocker administered by subcutaneous injection. Efgartigimod alfa injection (subcutaneous injection) is the proposed China International Nonproprietary Name for subcutaneous efgartigimod alfa injection and recombinant human hyaluronidase PH20. It is marketed in the United States as VYVGART Hytrulo and may be marketed under different names following approval in other regions. Zai Lab has an exclusive license agreement with argenx to develop and commercialize efgartigimod in mainland China, Hong Kong, Macau, and Taiwan (Greater China).